Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From the Phase 1/2 ACE-CL-001 Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 16
页数：3
相关论文
共 50 条
  • [1] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study
    Byrd, John C.
    Wierda, William G.
    Schuh, Anna
    Devereux, Stephen
    Chaves, Jorge M.
    Brown, Jennifer R.
    Hillmen, Peter
    Martin, Peter
    Awan, Farrukh T.
    Stephens, Deborah M.
    Ghia, Paolo
    Barrientos, Jacqueline C.
    Pagel, John M.
    Woyach, Jennifer A.
    Charuworn, Prista
    Hamdy, Ahmed
    Izumi, Raquel
    Patel, Priti
    Rothbaum, Wayne M.
    Wang, Min Hui
    Furman, Richard R.
    BLOOD, 2017, 130
  • [2] Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
    Byrd, John C.
    Wierda, William G.
    Schuh, Anna
    Devereux, Stephen
    Chaves, Jorge M.
    Brown, Jennifer R.
    Hillmen, Peter
    Martin, Peter
    Awan, Farrukh T.
    Stephens, Deborah M.
    Ghia, Paolo
    Barrientos, Jacqueline
    Pagel, John M.
    Woyach, Jennifer A.
    Burke, Kathleen
    Covey, Todd
    Gulrajani, Michael
    Hamdy, Ahmed
    Izumi, Raquel
    Frigault, Melanie M.
    Patel, Priti
    Rothbaum, Wayne
    Wang, Min Hui
    O'Brien, Susan
    Furman, Richard R.
    BLOOD, 2020, 135 (15) : 1204 - 1213
  • [3] Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/ Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1 /2 ACE-CL-001 Study
    Covey, Todd
    Gulranjani, Michael
    Cheung, Jean
    Bibikova, Elena
    Clevenger, Tracy
    Krantz, Fanny
    Pan, Karen
    Yamaguchi, Kyoko
    De Jong, Anouk
    Van Lith, Bart
    Mittag, Diana
    Izumi, Raquel
    Byrd, John C.
    Wierda, William G.
    O'Brien, Susan M.
    Furman, Richard R.
    Kaptein, Allard
    BLOOD, 2017, 130
  • [4] Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study
    Byrd, John C.
    Woyach, Jennifer A.
    Furman, Richard R.
    Martin, Peter
    O'Brien, Susan M.
    Brown, Jennifer R.
    Stephens, Deborah M.
    Barrientos, Jacqueline C.
    Devereux, Stephen
    Hillmen, Peter
    Pagel, John M.
    Chen, Dih-Yih
    Hamdy, Ahmed
    Izumi, Raquel
    Patel, Priti
    Wang, Min Hui
    Jain, Nitin
    Wierda, William G.
    BLOOD, 2018, 132
  • [5] Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study
    Byrd, John C.
    Woyach, Jennifer A.
    Furman, Richard R.
    Martin, Peter
    O'Brien, Susan
    Brown, Jennifer R.
    Stephens, Deborah M.
    Barrientos, Jacqueline C.
    Devereux, Stephen
    Hillmen, Peter
    Pagel, John M.
    Chen, Dih-Yih
    Hamdy, Ahmed
    Izumi, Raquel
    Patel, Priti
    Wang, Min Hui
    Jain, Nitin
    Wierda, William G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S283 - S283
  • [6] Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study
    Awan, Farrukh T.
    Schuh, Anna
    Brown, Jennifer R.
    Furman, Richard R.
    Pagel, John M.
    Hillmen, Peter
    Stephens, Deborah M.
    Hamdy, Ahmed
    Huang, Jane
    Izumi, Raquel
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [7] Acalabrutinib Monotherapy in Patients With Ibrutinib Intolerance: Results From the Phase 1/2 ACE-CL-001 Clinical Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 14 - 16
  • [8] Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study
    Hillmen, Peter
    Schuh, Anna
    Eyre, Toby A.
    Pagel, John M.
    Brown, Jennifer R.
    Ghia, Paolo
    Allan, John N.
    Wierda, William
    Hamdy, Ahmed
    Huang, Jane
    Izumi, Raquel
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [9] Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
    Furman, Richard R.
    Wierda, William G.
    Schuh, Anna
    Patten, Piers Em
    Chaves, Jorge M.
    Brown, Jennifer R.
    Munir, Talha
    Martin, Peter
    Awan, Farrukh T.
    Stephens, Deborah M.
    Ghia, Paolo
    Barrientos, Jacqueline C.
    Patel, Krish
    Woyach, Jennifer A.
    Butturini, Anna
    de Borja, Marianne
    Wang, Min Hui
    O'Brien, Susan
    Byrd, John C.
    BLOOD, 2022, 140 : 9873 - 9875
  • [10] Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
    Xu, Wei
    Song, Yongping
    Wang, Tingyu
    Yang, Shenmiao
    Liu, Lihong
    Hu, Yu
    Zhang, Wei
    Zhou, Jianfeng
    Gao, Sujun
    Ding, Kaiyang
    Zhang, Huilai
    Zhu, Zunmin
    Wang, Shun-Qing
    Xu, Bing
    Hu, Jianda
    Liu, Ting
    Ji, Chunyan
    Xia, Zhongjun
    Li, Yan
    Wang, Xin
    Zhu, Huaqiang
    Zhao, Renbin
    Zhang, Bin
    Xu, Zhixin
    Li, Jianyong
    BLOOD, 2020, 136
12345